Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Stratec SE (0RAR) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Stratec SE €3.10, price €21.85, upside -85.8%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
SS
Thin data
Sep 24, 2026
Stratec SE
0RAR · LSEWeakest SetupStrongly overvalued and low quality.
!Fair value €3.10 · Strongly overvalued (−85.8%)
!Quality 45/100
!Weak Growth (revenue 5y +0.1 %/yr)
!Loss-making · -1.4% net margin (TTM)
!Low debt · negative free cash flow
!2.7% dividend yield · Watch coverage
!Narrow moat 19/100
!Evidence only low, so the estimate is less certain
Watch Stratec SE for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range €15.86 – €132.20 · fair‑value band €3.10 – €6.15 · the €21.85 price screens above the €3.10 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers.
Show more
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
Stock analysis
Stratec SE (0RAR) currently trades at €21.85, while our model-based Fair Value estimate is €3.10, 85.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of €13.30 per share, and 1 of the 7 models we run sit above the €21.85 price.
Bear case: the DCF Models group reads lowest at €4.29, and 6 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: €3.10 (bear) to €6.15 (bull), the price of €21.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Stratec SE reported revenue of €251M in FY2025 versus €287M in FY2021, a compound −3.3%/yr. Reported net income was −€242K in FY2025.
Key figures
Market cap €266M · P/E ratio 0.1 · P/S ratio 0.90 · EPS (TTM) €3.25 · Dividend yield 2.7% · Net margin −0.1% · Return on equity −1.4% · Return on assets (EBIT) 7.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 29% below its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −86%, 0RAR screens richer than that median.
Fair Value models
Bear €3.10
Fair Value €3.10
Bull €6.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€2.00 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings
€1.52
€4.29
€7.66
72
Gordon GGM
€4.25
€7.12
€9.24
68
DDM Multi-Stage
€4.25
€6.20
€7.66
67
All 7 models by family
DCF Models
Owner Earnings
€1.52
€4.29
€7.66
72
Dividend Discount
Gordon GGM
€4.25
€7.12
€9.24
68
DDM Multi-Stage
€4.25
€6.20
€7.66
67
Multiples
EV/EBIT
€3.10
€6.16
€9.21
63
EV/EBITDA
€17.81
€25.77
€33.73
67
EV/Revenue
€0.4800
€3.28
€6.09
47
Asset-Based
NCAV (Graham)
€9.92
€13.30
€19.85
54
Notify me when 0RAR reaches fair value
Put 0RAR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
45/100
Of which business quality 45 · Market factors (momentum, volatility) 48
Profitability
22
Margins and returns on capital today
Quality Growth
15
Are margins and returns improving?
Cashflow
35
Earnings quality: real cash, not paper profit
Fin. Strength
50
Balance sheet, leverage, solvency risk
Investment
89
Disciplined investing over empire-building
Low Volatility
59
Calm price path (market factor)
Momentum
56
Price trend over the last 3–12 months (market factor)
52W Momentum
21
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Start year 2020 (pandemic). Over 10 years: +5.5% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.0% (2020) → 3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
0RAR screens overvalued: fair value 86% below the price. Compare with Abbott Laboratories, →
Compare Stratec SE with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 326 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Medical Devices median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $98.83 | $74.79 | −24% |
| Medtronic plc MDT | $87.09 | $65.61 | −25% |
| Stryker Corporation SYK | $278.77 | $306.65 | +10% |
| Boston Scientific Corporation BSX | $43.65 | $48.02 | +10% |
| Edwards Lifesciences Corporation EW | $85.19 | $81.94 | −4% |
| Siemens Healthineers AG SHL | €37.86 | €35.19 | −7% |
| DexCom, Inc DXCM | $86.68 | $95.35 | +10% |
| GE HealthCare Technologies Inc GEHC | $66.63 | $70.37 | +6% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.86 | ¥169.25 | +10% |
| Koninklijke Philips N.V PHIA | €21.87 | €15.23 | −30% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Stratec SE (0RAR) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of €3.10 versus a price of €21.85, about −86% upside (overvalued).
What is the fair value of 0RAR?
Our model-based fair value for Stratec SE is €3.10 (as of Sep 24, 2026), built from audited fundamentals. The current price: €21.85.
What is the quality score of 0RAR?
Stratec SE has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Stratec SE (0RAR)?
Our model-based price target is the fair value of €3.10 (as of Sep 24, 2026) from 7 valuation models. Cautious scenario €3.10, optimistic scenario €6.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Stratec SE stock forecast for 2026?
Our models put fair value at €3.10, about −86% upside versus a price of €21.85 (overvalued). Cautious scenario €3.10, optimistic scenario €6.15. The calculation is refreshed regularly with new filings.
What is the revenue of Stratec SE (0RAR)?
Stratec SE reported trailing-twelve-month revenue of about €244M (latest available figure, as of Sep 24, 2026).
Does Stratec SE pay a dividend?
Stratec SE currently shows a dividend yield of about 2.75% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Stratec SE (0RAR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Stratec SE it is €3.10 per share (as of Sep 24, 2026), against a price of €21.85. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Stratec SE stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0RAR trades above its calculated fair value: price €21.85, fair value €3.10, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RAR?
No. The price is what the market pays today (€21.85); the fair value is what the company's own numbers justify (€3.10). For Stratec SE the two are €18.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Stratec SE worth?
The market values Stratec SE at about €266M (market capitalisation, as of Sep 24, 2026). Per share that is €21.85; our models calculate a fair value of €3.10 per share.
What do the bullish and bearish scenarios say about 0RAR?
Our models span a range for Stratec SE: cautious scenario €3.10, base €3.10, optimistic €6.15 per share (as of Sep 24, 2026, price €21.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0RAR?
Stratec SE trades at a price-to-earnings ratio of 0.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €3.10 is built from several models across several years. Other multiples: P/B 1.1, P/S 1.1, EV/EBITDA 13.2.
How solid is the balance sheet of Stratec SE (0RAR)?
Balance-sheet figures for Stratec SE (as of Sep 24, 2026): return on equity −1.4%, debt of 0.40 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 0RAR from its 52-week high?
Stratec SE trades at €21.85, about 29% below its 52-week high of €30.97 and 38% above the low of €15.86 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €3.10 is for.
Which stocks are comparable to Stratec SE?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Stratec SE stock attractive at the current price?
The data as of Sep 24, 2026: price €21.85, calculated fair value €3.10 (−86%), Quality Score 45/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RAR calculated?
We run Stratec SE through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €3.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Stratec SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Stratec SE (0RAR)?
The closing price on Oct 2, 2026 was €21.85. Our model-based fair value is €3.10, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Stratec SE right now?
The price sits above even our optimistic bull case (€6.15). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€3.10 to €6.15) leaves room in how you read the outcome.
Where does the earnings growth of Stratec SE (0RAR) come from?
Earnings per share at Stratec SE grew −4.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.7 %, EBIT margin −5.8 %, tax rate −1.6 %, residual (interest, one-offs) −2.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Stratec SE
How large is the market capitalisation of Stratec SE (0RAR)?
The market capitalisation of Stratec SE is €266M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Stratec SE (0RAR)?
The price-to-sales ratio of Stratec SE is 0.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Stratec SE (0RAR)?
Earnings per share at Stratec SE are €3.25 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Stratec SE (0RAR)?
The dividend yield of Stratec SE is 2.7% (payout 18.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Stratec SE (0RAR)?
The net margin of Stratec SE is −0.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Stratec SE (0RAR)?
The return on equity (ROE) of Stratec SE is −1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Stratec SE (0RAR)?
On an EBIT basis the return on assets of Stratec SE is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Stratec SE (0RAR)?
The operating margin of Stratec SE is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Stratec SE (0RAR)?
Revenue at Stratec SE is growing −11.5% versus a year earlier (3y avg −3.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Stratec SE (0RAR)?
Earnings per share at Stratec SE are growing +109% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Stratec SE (0RAR) generate?
The free cash flow of Stratec SE is −€9.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Stratec SE (0RAR) carry?
The net debt of Stratec SE is €109M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Stratec SE in the live analysis
One click puts Stratec SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.